drugset / Trial / NCT04869943
Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
To demonstrate the efficacy of enobosarmin the treatment of androgen receptor positive (AR+) and estrogen receptor positive (ER+) metastatic breast cancer (MBC) as measured by radiographic progression free survival (rPFS).
Timeline
- Start
- 2021-10-12
- Primary completion
- 2024-01-09
- Completion
- 2024-01-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enobosarm | Small molecule | 9 mg | Oral |
| Comparator | Exemestane | Small molecule | — | — |
| Comparator | Everolimus | Small molecule | — | — |